妊娠期HIV感染者异烟肼与依非韦仑的药代动力学及药物相互作用:基因分型的重要性
异烟肼使CYP2B6正常代谢者依非韦仑清除率降低7%、慢/中间代谢者降低13%。
要点
- 妊娠使异烟肼清除率增加26%,依非韦仑清除率增加15%。
- NAT2和CYP2B6基因型是药物浓度的主要决定因素,快/慢代谢者间差异达5倍。
- 异烟肼对依非韦仑清除率的影响因CYP2B6基因型而异(降低7%–13%)。
核心结论
- 妊娠期异烟肼和依非韦仑暴露均降低,但药物浓度主要决定因素是NAT2和CYP2B6基因型。
主要发现
- 调整NAT2和CYP2B6基因型及体重后,妊娠使异烟肼清除率增加26%、依非韦仑清除率增加15%。
- 异烟肼使CYP2B6正常代谢者依非韦仑清除率降低7%,慢和中间代谢者降低13%。
- NAT2和CYP2B6基因型导致快与慢代谢者间两种药物浓度差异达5倍。
临床怎么用
- 临床应考虑NAT2和CYP2B6基因型对异烟肼和依非韦仑暴露的影响。
- 妊娠期需关注异烟肼和依非韦仑暴露降低及异烟肼-依非韦仑相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization guidelines recommend that individuals living with HIV receive ≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma isoniazid exposure during pregnancy, in the antiretroviral therapy era, has not been well-described. We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women. Eight hundred forty-seven women received isoniazid for 28 weeks, either during pregnancy or at 12 weeks postpartum, and 786 women received efavirenz. After adjusting for NAT2 and CYP2B6 genotype and weight, pregnancy increased isoniazid and efavirenz clearance by 26% and 15%, respectively. Isoniazid decreased efavirenz clearance by 7% in CYP2B6 normal metabolizers and 13% in slow and intermediate metabolizers. Overall, both isoniazid and efavirenz exposures were reduced during pregnancy, but the main determinants of drug concentration were NAT2 and CYP2B6 genotypes, which resulted in a five-fold difference for both drugs between rapid and slow metabolizers.
引用
- Gausi K, Wiesner L, Norman J, et al. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2020. PMID: 32909316. doi:10.1002/cpt.2044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。